Nanosphere Nets $32M in Stock Offering | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere has closed a public offering of common stock raising net proceeds of approximately $32.1 million, the firm said today.

The Northbrook, Ill.-based molecular diagnostics developer sold 15,686,000 shares of common stock at a price of $2.20 per share. Included in that share total is 2,046,000 shares issued to cover an over-allotment option.

Nanosphere said that it would use the funds for general corporate purposes and working capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.